274 related articles for article (PubMed ID: 17661640)
1. Controversies in the treatment of pneumococcal community-acquired pneumonia.
Feldman C; Anderson R
Future Microbiol; 2006 Oct; 1(3):271-81. PubMed ID: 17661640
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic resistance of pathogens causing community-acquired pneumonia.
Feldman C; Anderson R
Semin Respir Crit Care Med; 2012 Jun; 33(3):232-43. PubMed ID: 22718209
[TBL] [Abstract][Full Text] [Related]
4. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
6. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
7. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
Lee WK; Young BW
J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance and treatment of community-acquired pneumonia.
Mandell LA
Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
[TBL] [Abstract][Full Text] [Related]
10. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on "Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy".
Yu VL
Arch Intern Med; 2011 Jan; 171(2):172-3. PubMed ID: 21263107
[No Abstract] [Full Text] [Related]
11. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
Jacobs MR
Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
[No Abstract] [Full Text] [Related]
12. Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
Cunha BA
Postgrad Med; 2003 Jan; 113(1):42-4, 47-8, 52-4. PubMed ID: 12545592
[TBL] [Abstract][Full Text] [Related]
13. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
Yayan J
Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia.
Chenoweth CE; Saint S; Martinez F; Lynch JP; Fendrick AM
Mayo Clin Proc; 2000 Nov; 75(11):1161-8. PubMed ID: 11075746
[TBL] [Abstract][Full Text] [Related]
16. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
17. Hidden epidemic of macrolide-resistant pneumococci.
Klugman KP; Lonks JR
Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
[TBL] [Abstract][Full Text] [Related]
18. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.
Naucler P; Darenberg J; Morfeldt E; Ortqvist A; Henriques Normark B
Thorax; 2013 Jun; 68(6):571-9. PubMed ID: 23442364
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
20. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.
Jones RN; Jacobs MR; Sader HS
Int J Antimicrob Agents; 2010 Sep; 36(3):197-204. PubMed ID: 20558045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
